Gadobutrol
Gadavist, Gadobutrol (gadobutrol) is a small molecule pharmaceutical. Gadobutrol was first approved as Gadavist on 2011-03-14.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Gadavist, Gadobutrol
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| gadavist | New Drug Application | 2024-07-23 |
| gadobutrol | ANDA | 2024-10-24 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
GADOBUTROL, GADOBUTROL, HENGRUI PHARMA | |||
| 2024-04-29 | CGT | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| A9585 | Injection, gadobutrol, 0.1 ml |
Clinical
No data
Drug
General
| Drug common name | Gadobutrol |
| INN | gadobutrol |
| Description | Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
|
| Classification | Small molecule |
| Drug class | gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 770691-21-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2218860 |
| ChEBI ID | — |
| PubChem CID | 72057 |
| DrugBank | DB06703 |
| UNII ID | 1BJ477IO2L (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Gadavist, Gadobutrol
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use